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ARTICLE
Analysis of human acetylation stoichiometry
deﬁnes mechanistic constraints on protein
regulation
Bogi Karbech Hansen1, Rajat Gupta1, Linda Baldus2,3, David Lyon4, Takeo Narita 1, Michael Lammers2,3,
Chunaram Choudhary 1 & Brian T. Weinert1
Lysine acetylation is a reversible posttranslational modiﬁcation that occurs at thousands of
sites on human proteins. However, the stoichiometry of acetylation remains poorly char-
acterized, and is important for understanding acetylation-dependent mechanisms of protein
regulation. Here we provide accurate, validated measurements of acetylation stoichiometry at
6829 sites on 2535 proteins in human cervical cancer (HeLa) cells. Most acetylation occurs
at very low stoichiometry (median 0.02%), whereas high stoichiometry acetylation (>1%)
occurs on nuclear proteins involved in gene transcription and on acetyltransferases. Analysis
of acetylation copy numbers show that histones harbor the majority of acetylated lysine
residues in human cells. Class I deacetylases target a greater proportion of high stoichiometry
acetylation compared to SIRT1 and HDAC6. The acetyltransferases CBP and p300 catalyze a
majority (65%) of high stoichiometry acetylation. This resource dataset provides valuable
information for evaluating the impact of individual acetylation sites on protein function and
for building accurate mechanistic models.
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Lysine N-ε-acetylation is a reversible protein posttranslationalmodiﬁcation (PTM) that was ﬁrst identiﬁed on histones1. Inthe past decade, sensitive mass spectrometry (MS) techni-
ques enabled identiﬁcation of thousands of acetylation sites on
diverse cellular proteins2–4. Acetylation can be enzymatically
catalyzed by lysine acetyltransferases, however, recent data indi-
cates that acetylation also arises from nonenzymatic reaction with
acetyl-CoA5,6. Nonenzymatic acetylation potentially targets any
solvent accessible lysine residue, suggesting that nonenzymatic
acetylation sites are likely to greatly outnumber acetyltransferase-
catalyzed sites. As a result, enzyme-catalyzed acetylation is easily
overlooked within a vast background of nonenzymatic acetyla-
tion, presenting a needle-in-a-haystack problem for identifying
these sites. Proteome-wide analyses of lysine acetylation should
focus on identifying parameters that will help prioritize the
functional relevance of individual sites and provide mechanistic
insights. These parameters include regulation by acetyl-
transferases and deacetylases, dynamic turnover rates, and the
stoichiometry of modiﬁcation. Regardless of the origin of acet-
ylation, enzyme-catalyzed or nonenzymatic, understanding the
stoichiometry of modiﬁcation is important for determining the
impact of acetylation on protein function and for building
accurate mechanistic models.
We developed a quantitative proteomics method to determine
acetylation stoichiometry at thousands of sites by measuring
differences in the abundance of native and chemically acetylated
peptides6,7. We subsequently reﬁned our method by incorporat-
ing strict criteria for accurate quantiﬁcation of acetylated pep-
tides8. However, the stoichiometry of acetylation in human cells
remains poorly characterized.
Here we determine acetylation stoichiometry at thousands of
sites in human cervical cancer (HeLa) cells. We validate our
results using known quantities of peptide standards, using
recombinant acetylated proteins, and by comparison with acety-
lated peptide intensity. This high-conﬁdence dataset is used to
calculate acetylation copy numbers in cells, to explore the rela-
tionship between stoichiometry and regulation by acetyl-
transferases and deacetylases, and to reveal mechanistic
constraints on protein regulation by acetylation.
Results
Measuring acetylation stoichiometry. We measured acetylation
stoichiometry in HeLa cells using partial chemical acetylation and
serial dilution SILAC (SD-SILAC) to ensure quantiﬁcation
accuracy8 (Fig. 1a). Two independent biological replicates were
performed, each using a different degree of chemical acetylation
and inverting the SILAC labeling between experiments. The
degree of chemical acetylation was estimated based on the median
reduction of unmodiﬁed peptides generated by tryptic cleavage at
one or two lysine residues (Supplementary Figure 1a). Based on
the estimated degree of chemical acetylation, we performed a
serial dilution of the chemically acetylated peptides to give
median ~1%, ~0.1%, and ~0.01% chemical acetylation. Acetylated
peptides were enriched and the differences between native
acetylated and chemically acetylated peptides quantiﬁed by MS
(Supplementary Data 1a). To ensure accurate quantiﬁcation, we
required that the abundance of native acetylated peptides was
quantiﬁed by comparison with at least two different concentra-
tions of chemically acetylated peptides, and that the measured
SILAC ratios agreed with the serial dilution series. SILAC ratios
that did not follow the dilution series (allowing up to two-fold
variability) were deﬁned as being inaccurately quantiﬁed, even
though one of the measurements may be correct. Quantiﬁcation
error was reduced when the concentration of chemically acety-
lated peptides was most similar to native acetylated peptides
(Fig. 1b). However, quantiﬁcation error was substantially higher
than in our previous experiments in bacteria8, likely due to the
greater complexity of the human proteome. The high error rates
highlight the need to control for quantiﬁcation accuracy, and
show that comparing native acetylated peptides to just 1% che-
mically acetylated peptides results in a majority of false quanti-
ﬁcation (Fig. 1b). The measured stoichiometry of acetylated
peptides was signiﬁcantly and highly correlated between inde-
pendent experimental replicates (Fig. 1c). The precision of our
measurements was also highly reproducible; the median ratio of
stoichiometry between replicates was 0.95, and 90% of the mea-
surements varied by less than a factor of two between replicates
(Fig. 1d).
For high stoichiometry (>10%) acetylation, the difference
between native acetylated and chemically acetylated peptides
becomes too small to accurately measure by SILAC quantiﬁca-
tion, which is typically limited to differences greater than 2-fold
in magnitude. At 5% partial chemical acetylation, a peptide with
90% stoichiometry will have a SILAC ratio of 1.006, and a peptide
with 50% stoichiometry will have a SILAC ratio of 1.05
(Supplementary Figure 1b). These differences are too small to
accurately resolve, and can result in inaccurate stoichiometry
measurements that are out of bounds (greater than 100% or
negative). Due to the inherent limitations in calculating
stoichiometry for these peptides, we set a cutoff of maximum
10% stoichiometry, and classiﬁed all sites exceeding this cutoff as
having >10% stoichiometry. Only 16 peptides met these criteria,
and they harbored previously known high stoichiometry acetyla-
tion sites (Supplementary Data 1a), including; histones H3 K23
(2 different peptides), H3 K14, and H4 K16. Other peptides
harbored sites on acetyltransferases, such as CBP K1583
(2 different peptides) and N-alpha-acetyltransferase 50 K33, or
on proteins that catalyze reactions using acyl-CoAs, such as
hydroxymethylglutaryl-CoA lyase K48 and dihydroxyacetone
phosphate acyltransferase K643. These data show that, although
we are unable to accurately measure high stoichiometry
acetylation, we were able to identify these peptides, they represent
known or probable high stoichiometry acetylation sites, and they
constitute a small portion (0.2%) of the peptides analyzed.
Validating stoichiometry measurements. We used known
quantities of unmodiﬁed and acetylated peptide standards
(AQUA peptides) to determine stoichiometry directly at ten sites
on three proteins, cortactin (CTTN), nucleolin (NCL), and N-
acetyltransferase 10 (NAT10) (Supplementary Data 1b). Stoi-
chiometry determined by partial chemical acetylation (PCA) was
signiﬁcantly correlated (r= 0.94) with stoichiometry determined
using AQUA peptides (Fig. 1e). Furthermore, stoichiometry
measurements differed by a factor of two or less for a majority
(7/10) of the analyzed peptides (Fig. 1f). Three sites showed 3.4-,
6-, and 7-fold higher stoichiometry by PCA, indicating over-
estimation of stoichiometry by PCA or underestimation by
AQUA. These differences occurred at the site-level and were
therefore not attributable to errors in protein quantiﬁcation.
We think that the agreement between these two methods is
notable when considering all possible sources of variability in
each measurement.
We further validated our measurements using two recombi-
nant, site-speciﬁcally acetylated proteins; malate dehydrogenase
(MDH2) K239ac and hydroxymethylglutaryl-CoA lyase
(HMGCL) K48ac. Recombinant acetylated proteins (SILAC-
light-labeled) were used as a spike-in standard to measure
acetylation stoichiometry in SILAC-heavy-labeled HeLa lysate.
Stoichiometry measured using two different concentrations of
recombinant acetylated protein (spike-in) agreed with our
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09024-0
2 NATURE COMMUNICATIONS |         (2019) 10:1055 | https://doi.org/10.1038/s41467-019-09024-0 | www.nature.com/naturecommunications
measurements using PCA, further supporting the accuracy of our
stoichiometry dataset (Fig. 1g).
Stoichiometry measurements were additionally validated by
comparison to acetylated peptide intensity that was corrected for
differences in protein abundance. We previously showed that
abundance-corrected intensity (ACI) is correlated to acetylation
stoichiometry in yeast6. ACI was signiﬁcantly correlated with
acetylation stoichiometry in HeLa cells (Supplementary
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Fig. 1 Measuring acetylation stoichiometry. a Diagram of the method used to measure acetylation (Ac) stoichiometry. b The degree of quantiﬁcation error
as determined by the fraction of SILAC ratios at each concentration of chemically acetylated peptides that was not consistent with SILAC ratios measured
in at least one different concentration of chemically acetylated peptides. c The correlation between stoichiometry measured in independent experimental
replicates. The number of peptides (n), Pearson’s correlation (r), and P-value (P) of correlation are shown. d Low absolute variability between experimental
replicates. The histogram shows the distribution of Log2 ratios of stoichiometry in Experiment 1/Experiment 2 (Exp.1/Exp.2). e The correlation between
stoichiometry measured using partial chemical acetylation (PCA) and absolute quantiﬁcation (AQUA) peptide standards. f Low absolute variability
between stoichiometry measurements made by PCA and AQUA. g Validation of stoichiometry measurements using recombinant acetylated (100%)
proteins as a spike-in standard. Stoichiometry was measured at two different concentrations of spike-in protein (SILAC light, red) compared to SILAC
heavy-labeled HeLa (blue) for each acetylation site. Source data are provided as a Source Data ﬁle
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Figure 1c), however, the predictive power of this correlation was
modest (r= 0.48–0.52). There are several reasons for this modest
correlation. Firstly, peptide intensity is inherently variable.
Secondly, protein abundance estimates may be inaccurate. We
found that outlier data points using iBAQ-based protein
abundance were not outliers when using copy-number-based
protein abundance (Supplementary Figure 1c), indicating that
variability in protein abundance measurements contributes to
disagreement between ACI and stoichiometry measurements.
Thirdly, antibody-based acetylated peptide enrichment may be
peptide-sequence biased, which will introduce further variability.
Regardless of these limitations, ACI provides an easy method to
estimate the relative stoichiometry of acetylation sites, and the
signiﬁcant correlation with our stoichiometry measurements by
PCA provides further support for the accuracy of our
measurements.
Copy number limits the detection of acetylated peptides. The
detection of acetylated peptides is biased to abundant proteins
(Fig. 2a). Furthermore, the fraction of lysines that are detected as
acetylated on any given protein is signiﬁcantly correlated with
protein abundance (Fig. 2b). This bias is found in every acetylome
dataset that we have examined (Supplementary Figure 2a)9–12,
and indicates that acetylation occurs on most lysine residues in
cells and that protein abundance is a limiting factor in the
detection of acetylated peptides. These data further support the
notion that all solvent accessible lysine residues are acetylated to
some degree, either enzymatically or nonenzymatically.
Deep proteome measurements detect unmodiﬁed peptides
from proteins whose abundance spans seven orders of magnitude
(Fig. 2a)13. This raises the question of why we detect so few
acetylated peptides without antibody enrichment (Fig. 2c). The
signal intensity of acetylated peptides is comparable to unmodi-
ﬁed peptides in the mass spectrometer (Supplementary Figure 2b,
c), indicating that we should be able to detect acetylated peptides
as readily as unmodiﬁed peptides. We compared copy numbers
for unmodiﬁed peptides to copy numbers for acetylated peptides
as determined from our stoichiometry measurements. The
distribution of acetylated peptide copy number shows that, in
the absence of acetylated peptide enrichment, most acetylated
peptides are at or below the detection limit of the mass
spectrometer, even in deep proteome measurements (Fig. 2d).
In contrast, acetylated peptides that were detected without
antibody enrichment occurred at copy numbers that were within
the detectable range of unmodiﬁed peptides (Fig. 2e). Thus, our
stoichiometry measurements are consistent with the inability to
detect acetylated peptides without enrichment. Strikingly, our
data indicate that some acetylation events are so rare that they
occur at a copy number that is less than one per cell (Fig. 2d).
Properties of high stoichiometry acetylation. We measured the
stoichiometry of acetylated peptides; however, individual acet-
ylation sites may occur on multiple different peptides due to
incomplete tryptic digestion, protein N-terminal acetylation, or
oxidized methionine residues. To examine acetylation stoichio-
metry at the site-level, we calculated the summed stoichiometry of
peptides containing the same acetylation site (Supplementary
Data 1c). This resulted in stoichiometry measurements for
6829 sites, with a median stoichiometry of just 0.02% (1/4000
molecules) (Fig. 3a). This represents very low levels of acetylation
for most sites, only 1% (66 sites) displayed stoichiometry >1%,
and ~15% (1014 sites) displayed stoichiometry >0.1%.
We performed UniProt keyword enrichment analysis to
examine the functional categories of proteins that are associated
with higher stoichiometry (>0.23% or >1%) acetylation (Fig. 3b).
Higher stoichiometry acetylation was overrepresented on nuclear
proteins involved in chromatin regulation and transcription. This
observation is consistent with the known nuclear functions of
acetyltransferases, deacetylases, and acetylated lysine-binding
bromodomain proteins. In fact, the keywords Bromodomain
and Acetyltransferase were signiﬁcantly enriched in the group of
proteins with high stoichiometry acetylation. We were unable to
calculate stoichiometry for doubly acetylated peptides because of
the low frequency of chemical acetylation at both positions.
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However, given the low stoichiometry of acetylation, doubly
acetylated peptides are unlikely to occur by random chance and
most likely reﬂect the activity of acetyltransferases. Consistent
with this idea, doubly acetylated peptides occurred on proteins
that were overrepresented for the same UniProt keywords that
were associated with high stoichiometry acetylation (Fig. 3b).
Thus, sites occurring on doubly acetylated peptides may occur at
high stoichiometry and are likely to be enzyme-catalyzed.
To investigate the relationship between stoichiometry and
subcellular compartmentalization we used immunoﬂuorescence-
based protein localization as determined by the Human Protein
Atlas14. Acetylation stoichiometry was broadly distributed and
mostly similar in every subcellular compartment analyzed
(Fig. 3c). Mitochondrial acetylation occurred at a slightly, yet
signiﬁcantly (P < 5e−5, Wilcoxon test), higher median stoichio-
metry. However, mitochondria contained the smallest fraction of
high (>1%) stoichiometry acetylation sites. In contrast, the
nucleus contained the greatest fraction of high stoichiometry
sites, which was approximately an order of magnitude greater
than in mitochondria (Fig. 3c).
We used IceLogo15 to determine whether high stoichiometry
acetylation was associated with neighboring amino acids.
Cysteine residues were notably overrepresented for sites with
>0.23% stoichiometry (10-fold higher than median stoichiome-
try), particularly in the −4, −3, and −2 positions (Fig. 3d).
However, this bias was absent when examining sites with >1%
stoichiometry, indicating that this overrepresentation was asso-
ciated with sites with moderately elevated stoichiometry.
Remarkably, sites with cysteine residues in the −4, −3, or −2
position constituted 35% (159/460) of the sites with >0.23%
stoichiometry. UniProt keyword enrichment analysis of the
proteins harboring these sites found a variety of enriched
keywords (Supplementary Data 1d). However, unlike high
stoichiometry acetylation in general (Fig. 3b), keywords describ-
ing processes associated with nuclear acetyltransferases, such as
Nucleus, Transcription, and Chromosome were notably absent.
These data suggest that cysteine residues may promote none-
nzymatic acetylation of downstream lysine residues, and these
sites constitute a substantial portion (35%) of sites with an
elevated (>0.23%) stoichiometry of acetylation. This conclusion is
a
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supported by a recent study that uncovered a similar bias for
higher stoichiometry acetylation at sites with proximal cysteine
residues16.
Histone acetylation. We measured stoichiometry at 57 histone
sites and found that high stoichiometry acetylation was mostly
restricted to sites on the N-terminal tails of core histones H2B,
H3, and H4 (sites on H2A were not measured) (Fig. 4a). The
stoichiometry of histone H3 and H4 acetylation sites has been
extensively studied17–20, and our measurements are comparable
to these previous measurements (Fig. 4b). However, our method
does not measure the stoichiometry of doubly acetylated peptides
that can arise from the lysine-rich N-terminal tails of the core
histones H2A, H2B, H3, and H4. Feller et al.18 found that the
stoichiometry of mono-acetylated histones H3 and H4 were more
abundant than di-acetylated H3 and H4, with the exception of H4
K5+ K12 and H3 K18+ 23 (which is more abundant than K18
alone, but less abundant than K23 alone). We detected doubly
acetylated peptides containing the following sites on H2A (K5+
K9, K9+ K11, K11+K13), H2B (K5+K11, K11+ K12, K15+
K16, K16+ K20, K20+K23, K34+ K43, and K116+K120), H3
(K9+ K14, K18+ K23, and K27+ K36), and H4 (K8+ K12 and
K12+K16). The stoichiometry of di-acetylated peptides remains
unexplored for H2B, and these peptides may be more abundant
than their mono-acetylated counterparts used to calculate stoi-
chiometry in this study. In addition, some acetylated peptides
from histone tails may not be detected because of their small size.
Thus, our estimates of histone acetylation stoichiometry may
underestimate the actual native stoichiometry at these positions
because these sites also occur on di-acetylated peptides or pep-
tides that we are unable to detect with our methodology.
Regardless, our data suggest that the stoichiometry of H2B
acetylation ranges from 0.5% to 5.6%. N-terminal H2B sites are
primarily acetylated by the CBP/p300 acetyltransferases12, which
also target H3K27 and H3K36. N-terminal H2B sites (K5, K11,
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Fig. 4 Stoichiometry of histone acetylation. a The diagram shows all histone acetylation sites whose stoichiometry was determined in this study. The sites
are ordered by descending stoichiometry. Note that high stoichiometry sites occur on the N-termini of core histones. b The stoichiometry of histone
acetylation sites as determined in four independent studies17–20. c An anti-acetylated lysine immunoblot of HeLa whole cell lysate. Cells were boiled in 2%
LDS to ensure histone extraction. Histones are annotated based on their expected molecular weight. d Histone acetylation sites constitute a majority of
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K12, K15, and K16) show faster deacetylation kinetics compared
to K2012. Interestingly, the stoichiometry of K20 is greater than
K5, indicating that the lower stoichiometry at K5 is possibly due
to its more rapid turnover.
Histones are some of the most abundant and most highly
acetylated proteins in cells. Anti-acetylated lysine antibodies
prominently detect histone acetylation in western blots of whole
cell lysates, suggesting that histones harbor most of the acetylated
lysine residues in cells (Fig. 4c). Using our acetylated lysine copy
number estimates we found that histone acetylation accounted for
74% of the acetylated lysine residues in cells (Fig. 4d). If we
include histone sites whose stoichiometry was measured by
independent studies17–20, the fraction of acetylated lysines
occurring on histones increases to 84% (Fig. 4d). These estimates
do not account for several sites on H2B (K11, K12, K15, K16, and
K23), as well as sites on H2A (K4, K5, K7, K9, K11, and K13).
Thus, histone acetylation likely accounts for an even greater
proportion of the acetylated lysine residues found in cells.
Regulation by deacetylases. We analyzed the stoichiometry of
lysine deacetylase (KDAC)-regulated acetylation sites by com-
paring the data obtained in this study with a previous analysis of
deacetylase inhibitors in HeLa cells21. Class I KDACs (HDAC 1,
2, 3, and 8) are speciﬁcally targeted by the class I inhibitors
apicidin, MS-275, valproic acid, and sodium butyrate; the class IIb
KDAC HDAC6 is speciﬁcally targeted by tubacin; and nicotina-
mide inhibits the activity of NAD+-dependent Sirtuin deacety-
lases, but mostly affected SIRT1-regulated sites in mammalian
cells21. To analyze class I KDAC regulated sites, we used the
median increased acetylation caused by apicidin, MS-275, val-
proic acid, and sodium butyrate.
KDAC inhibitors regulated sites with a broad range of
stoichiometry (Fig. 5a). Class I KDAC inhibitors regulated
substantially greater proportions of moderately increased
(>0.23%) and high stoichiometry (>1%) acetylation compared
to tubacin or nicotinamide. The stoichiometry of class I regulated
sites was signiﬁcantly higher than not-regulated (NR) sites, while
the distributions of tubacin and nicotinamide regulated sites was
not signiﬁcantly different than NR sites. Furthermore, sites that
were most sensitive to KDAC inhibitors (>4× increased
acetylation) showed an increasing proportion of higher stoichio-
metry sites for the class I inhibitors, but stayed the same or
decreased for tubacin and nicotinamide (Fig. 5a). Thus, while
tubacin and nicotinamide regulate a greater portion of the
acetylation sites quantiﬁed in this study (8.6% and 8.8%,
respectively) than class I inhibitors (2.6%), the class I inhibitors
regulate a greater proportion of higher stoichiometry acetylation.
Regulation by the CBP and p300 acetyltransferases. The
homologous Creb-binding protein (CBP)/E1A-binding protein
p300 (p300) acetyltransferases are important regulators of cell-
type-speciﬁc and signaling-regulated gene expression22. CBP/
p300 acetyltransferase activity is essential for promoting gene
transcription and CBP/p300 targets a large proportion of the
acetylome12. CBP/p300-regulated sites constituted 12.7% of the
sites analyzed in this study, indicating that CBP/p300 targets
more than one out of every ten acetylation sites. CBP/p300 tar-
geted a similar proportion (11.5%) of low stoichiometry ( < 0.2%)
sites, and an increasing proportion of higher stoichiometry sites,
up to 65% of the sites with stoichiometry exceeding 1% (Fig. 5b).
Thus, CBP/p300 acetylates a majority of high (>1%) stoichio-
metry acetylation sites. The stoichiometry of CBP/p300-regulated
sites also increased with the degree of downregulated acetylation
in the absence of CBP/p300 catalytic activity (Fig. 5c), indicating
that the sites most affected by loss of CBP/p300 tend to be more
highly acetylated.
Stoichiometry of functionally characterized sites. The activity
and subcellular localization of eukaryotic translation initiation
factor 5 A (eIF5A) is regulated by PCAF-catalyzed acetylation at
K4723. We found that eIF5A was more than 10% acetylated at
K47, consistent with a regulatory role for acetylation at this
position. DNA methyltransferase 1 (DNMT1) is acetylated by the
TIP60 acetyltransferase, and acetylation promotes ubiquitin-
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dependent protein turnover24. We found that DNMT1 harbored
high stoichiometry acetylation at K335 (0.57%) and K675 (0.1%).
Pyruvate dehydrogenase E1 alpha 1 subunit (PDHA1) is acety-
lated at K321 by acetyl-CoA acetyltransferase 1 (ACAT1), which
recruits PDH kinase (PDK) to inhibit pyruvate dehydrogenase
activity25. We found that PDHA K321 was 0.6% acetylated,
supporting high stoichiometry acetylation at this position.
Glucose-6-phosphate dehydrogenase (G6PD) is reported to be
negatively regulated by KAT9-dependent acetylation of K403, and
activated by SIRT1-dependent deacetylation26. We found that
G6PD is just 0.02% acetylated at K403. Acetylation of
phosphoglycerate kinase 1 (PGK1) at K220 disrupts its activity
by inhibiting binding to ADP27. We found that PGK1 is 0.03%
acetylated at K220 in HeLa cells. PCAF is reported to regulate
cyclin dependent kinase 2 (CDK2) activity by acetylating CDK2
at K33 in the ATP-binding active site28. We found that CDK2
K33 is just 0.05% acetylated, however, CDK1 K33 was 4.5%
acetylated, suggesting that acetylation may play a greater role in
regulating CDK1 activity3. In each of the above examples,
acetylation is reported to reduce enzymatic activity, however, the
stoichiometry of acetylation suggests that acetylation would need
to be dramatically increased (100-fold or more) in order to have a
substantial impact on protein function.
Low stoichiometry acetylation does not necessarily indicate a
lack of function. Rather, the mechanism-of-action determines
whether low stoichiometry acetylation is sufﬁcient to regulate
protein function. Acetylation that imparts a gain-of-function or
regulates protein activity at a speciﬁc time and/or place, could be
regulated by low stoichiometry acetylation. For example, acetyla-
tion at K220 regulates the activity of microtubule associated
protein RP/EB family member 1 (EB1), speciﬁcally during mitosis
and at spindle microtubule plus ends29. Although we found that
EB1 K220 was only 0.02% acetylated, the mechanism-of-action is
consistent with the low observed stoichiometry of modiﬁcation.
Discussion
Here we provide a validated resource of acetylation stoichiometry
at thousands of sites in the most widely studied human cell line
(HeLa). Our data shows that the vast majority of acetylation
occurs at very low stoichiometry. Thus, as a general rule, the
mechanisms by which acetylation regulates protein function
should agree with a low stoichiometry of modiﬁcation. There are
a large number of metabolic enzymes whose catalytic activity is
reduced by site-speciﬁc acetylation30. Many studies relied on
acetylation mimicking glutamine-substitution mutations to assay
the impact of acetylation on these proteins, a method that results
in 100% stoichiometry of modiﬁcation. However, our measure-
ments indicate that the vast majority of acetylation occurs at a
stoichiometry that is much less than 1%, and is therefore not
likely to impact protein activity through a loss-of-function
mechanism at a single acetylation site. Low stoichiometry acet-
ylation is compatible with gain-of-function mechanisms, or in
processes that are spatially or temporally restricted. However,
even for gain-of-function mechanisms such as increased catalytic
activity, a high degree of acetylation may be required to have a
measurable impact on overall activity. Thus, understanding the
stoichiometry of acetylation is important for formulating accurate
mechanistic models when evaluating the impact of acetylation on
protein function. High stoichiometry sites may be particularly
interesting because they are more likely to be enzyme-catalyzed.
However, more studies are required to determine if high stoi-
chiometry is a good indicator of functional importance. Enzy-
matic acetylation does not necessarily indicate a regulatory
function, and high stoichiometry acetylation may also occur by
nonenzymatic mechanisms.
We previously showed that the Sirtuin deacetylases SIRT3 and
CobB suppress acetylation at hundreds of sites to levels that are
equal to or less than the median stoichiometry of modiﬁcation7,8.
These data support the idea that Sirtuin deacetylases may have a
general role suppressing nonenzymatic acetylation to preserve
protein function31. Here we ﬁnd that SIRT1 and HDAC6 also
suppress acetylation at regulated sites to levels that are compar-
able to the median stoichiometry of acetylation. SIRT1 likely
suppresses the activity of nuclear acetyltransferases, ensuring
tight control over the sites targeted by these enzymes. HDAC6
deacetylates a large number of cytoplasmic acetylation sites, most
of which are acetylated by unidentiﬁed acetyltransferases, or
nonenzymatically. Interestingly, the HDAC6 inhibitor Bufexamac
sensitizes cells to nonenzymatic acetylation caused by aspirin32,
suggesting that HDAC6 may have a role in protecting cells from
nonenzymatic acetylation stress. It is important to note that the
activity of these deacetylases as general suppressors of acetylation
at hundreds of sites, or as dynamic regulators of individual
acetylation sites, is not mutually exclusive. Deacetylases may also
target hundreds of acetylation sites for no reason whatsoever; if
such activity is not evolutionarily disadvantageous, it will not be
selected against.
Our data highlights the outsized impact of CBP and p300 on
the acetylome. CBP/p300 targets up to 20% of all acetylation sites
in cells, and acetylates proximal proteins in a sequence-
independent manner12. Here we ﬁnd that CBP/p300 targets a
majority (65%) of high (>1%) stoichiometry acetylation. How-
ever, CBP/p300 also acetylated many sites to a low stoichiometry
of modiﬁcation. These low stoichiometry sites likely include both
functionally important regulatory acetylation and non-functional,
off-target acetylation. This presents a challenge to prioritizing
sites for mechanistic analyses and suggests that additional para-
meters, such as dynamic turnover rates12 and conditional reg-
ulation, are needed to identify potentially interesting sites.
Several other groups have also used chemical acetylation to
measure acetylation stoichiometry, often reporting substantially
higher stoichiometry than we observed in our experiments19,33,34.
One crucial difference between these studies and our own is that
we use a low degree of chemical acetylation (~5–10%) and dilute
the fraction of chemically acetylated peptides to allow for accurate
quantiﬁcation8. Other studies used stable-isotope-labeled acet-
ylating agents, such acetic anhydride and NHS-acetate, to com-
pletely acetylate all free lysine residues and isotopically label the
chemically acetylated fraction at the same time19,33,34. While this
is an elegant approach, incomplete isotopic labeling of the acet-
ylating agents limits the resolution to stoichiometry greater than
1–2%, and it is not possible to independently dilute the chemi-
cally acetylated peptides to ensure accurate quantiﬁcation. Most
of these studies19,33–35 did not validate their results using
orthogonal methods, and the accuracy of their measurements is
likely impacted by the limited dynamic range of accurate quan-
tiﬁcation by mass spectrometry36,37. One study found that ~75%
of their measurements were impacted by false quantiﬁcation19,
and we found that ~90% of our measurements were inaccurate
when quantifying the differences between completely (100%)
acetylated peptides and native acetylated peptides8. The differ-
ences between 100% acetylated and native acetylated peptides are
likely too large to be accurately quantiﬁed by MS. Given the
differences in acetylation stoichiometry reported by independent
studies, care should be taken to carefully validate these
measurements.
The paucity of high stoichiometry acetylation detected in our
study is somewhat disappointing. However, as we show, it is
consistent with the inability to detect acetylated peptides in deep
proteome measurements. One possibility is that proteins are
deacetylated during protein extraction, resulting in uniformly
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decreased acetylation. We consider this unlikely for several rea-
sons. We and others can quantify acetylation changes that occur
in vivo, indicating that these differences are preserved during
protein extraction. We furthermore compared acetylation after
lysing cells by three different methods and found that acetylation
levels were unaffected by the method of protein extraction
(Supplementary Figure 3). Thus, we believe that our measure-
ments indicate the stoichiometry of acetylation that occurs on
proteins inside cells.
Methods
Cell culture. HeLa (ATCC: CCL-2) cells were tested for mycoplasma con-
tamination and grown in DMEM supplemented with 10% FBS, 2 mM L-glutamine,
and 1% penicillin/streptomycin. SILAC media was supplemented with arginine and
lysine (SILAC Light) or with heavy isotope-labeled arginine (13C6,15N4-arginine,
Sigma) and lysine (13C6,15N2-lysine, Cambridge Isotope Laboratories) (SILAC
heavy) in media containing dialyzed serum (Sigma). Cells were cultured at 37 °C in
a humidiﬁed incubator at 5% CO2. At a conﬂuency of ~90%, cells were washed
twice with PBS and lysed in ice-cold modiﬁed RIPA buffer (50 mM Tris, pH 7.5,
150 mM NaCl, 1 mM EDTA, 1x mini complete protease inhibitor cocktail (Roche),
10 mM nicotinamide, and 5 μM trichostatin A). Lysates were mixed with 1/10
volume of 5M NaCl to release chromatin-bound proteins and incubated for 15 min
on ice. Subsequently, lysates were homogenized by sonication (6 × 10 sec, 15W),
cleared by centrifugation (20,000 × g, 15 min, 4 °C), and the supernatant pre-
cipitated by addition of four volumes of −20 °C acetone. Precipitates were re-
dissolved in 8M guanidine HCl, 50 mM Hepes pH8.5 and protein concentration
was determined by Quick-start Bradford assay (Bio-Rad).
Chemical acetylation. Protein lysates in 8M guanidine HCl were mixed with 1/10
volume 1M acetyl-phosphate (Sigma) prepared in H2O, and the acetylation
reaction was allowed to proceed for 2 h at 37 °C. Control reactions were prepared
by mixing with 1/10 volume H2O. The acetyl-phosphate was quenched by diluting
the reaction ﬁve-fold in 8M Guanidine HCl, 100 mM Tris pH8. Control and
chemically acetylated SILAC-labeled protein lysates were mixed in equal portions
according to the protein concentration as determined by Bradford assay (above).
The samples were digested (described below) and analyzed by mass spectrometry
to determine the degree of partial chemical acetylation (PCA) (Supplementary
Figure 1a). The measured SILAC ratios were additionally used to adjust the mixing
of SILAC lysates in subsequent experiments.
Protein digestion. Protein lysates were reduced and alkalated with 5 mM TCEP
and 5 mM chloracetamide for 45 min at room temperature. Approximately 10 mg
protein per condition was diluted to 2M guanidine HCl with 50 mM Hepes, pH8
and digested by endoproteinase Lys C (1:200 w/w; Wako) for 2 h at room tem-
perature. The lysates were further diluted to 1M guanidine HCl and digested with
trypsin protease (1:200 w/w; Sigma-Aldrich) for 16 h at 37 °C. Digestion was
stopped by the addition of triﬂuoroacetic acid (TFA) to a ﬁnal concentration of 1%.
Digests were cleared by centrifugation (2500 × g, 5 min) and loaded onto reversed-
phase C18 Sep-Pak columns (Waters), pre-equilibrated with 5 ml acetonitrile and
2 × 5ml 0.1% TFA. Peptides were washed with 0.1% TFA and H2O, and eluted
with 50% acetonitrile.
Acetylated peptide enrichment. Peptide concentration was determined by UV
spectrometry. The ﬁrst experiment was performed in technical replicates using two
different peptide fractionation strategies. In the ﬁrst strategy, peptides were pre-
fractionated by high pH reversed-phase chromatography11 to 6 fractions followed
by acetylated peptide enrichment and micro-scale (in stage-tip) scale strong cation
exchange (SCX) chromatography to an additional 3 fractions (pH4.5, 5.5, and 9.0),
for a total of 18 fractions. The second strategy was to perform acetylated peptide
enrichment on the entire peptide digest, followed by micro-scale SCX into 5
fractions (pH3.5, 4.0, 4.5, 5.5, and 9.0). The second experiment was performed
using the second fractionation strategy only. For acetylated peptide enrichment, the
peptides were mixed with 100 µl 10x IP buffer (500 mM MOPS; pH 7.2, 100 mM
Na-phosphate, 500 mM NaCl, 5% NP-40) per 5 mg peptides. The acetonitrile was
removed and the volume reduced to ~1 ml, by vacuum centrifugation. The ﬁnal
volume was adjusted with H2O to a concentration of 5 mg/ml. 40 μl of anti-
acetylated lysine antibody (PTMScan Acetyl-Lysine Motif [Ac-K] Kit, Cell Sig-
naling Technology) was washed 3× in 1 mL IP buffer, the peptides were clariﬁed by
centrifugation at 20,000 × g for 5 min, and the peptide supernatant was mixed with
the anti-acetylated lysine antibody. Peptides were enriched overnight at 4 °C,
washed 3 × in 1 ml cold (4 °C) IP buffer, 4× in 1 ml cold IP buffer without NP-40,
and 1× in 1 ml H2O. All wash buffer was removed using a 26 gauge needle on an
aspirator. Acetylated peptides were eluted with 100 μl 0.15% TFA, repeated for a
total of three times. Peptides were loaded directly onto a micro-SCX column,
fractionated as described above, and de-salted on C18 stage-tips38.
Mass spectrometry. Peptides were analyzed by nanoﬂow liquid chromatography-
coupled tandem mass spectrometry (nLC-MS/MS) using a Proxeon easy nLC 1200
connected to a Q-Exactive HF mass spectrometer (Thermo Scientiﬁc). The Q-
Exactive was operated in proﬁle mode using positive polarity and a Top10 data
dependent acquisition (DDA) method with the following settings: Spray voltage=
2 kV, S-lens RF level= 50, heated capillary= 275 °C. Full scan (MS1) was per-
formed with an m/z range of 300–1750 at 60,000 resolution with a target value of
3 × 106 ions and a maximum ﬁll time of 20 milliseconds (ms). Fragment (MS2)
scans were performed at a resolution of 15,000 with a target value of 5 × 104 ions, a
maximum injection time of 110 ms, an isolation width of 1.3 m/z, a normalized
collision energy (NCE) of 28, and a ﬁxed ﬁrst mass of 100 m/z. Peptide were
separated by nanoﬂow chromatography using an EASY-nLC 1000 system (Thermo
Scientiﬁc) connected to a 15 cm capillary column packed with 1.9 μm Reprosil-Pur
C18 beads (Dr. Maisch). Column temperature was maintained at 40 °C using an
integrated column oven (PRSO-V1, Sonation GmbH) Peptides were eluted by a
gradient of acetonitrile (ACN) in 0.1% formic acid. A typical run utilized a 120 min
gradient followed by 15 min wash and equilibration. A linear gradient at 250 nl/
min of 8-24% ACN (90 min) and 24–40% ACN (30min) was followed by a wash at
40–80% ACN (5 min) and 80%–8% ACN (5 min), and equilibration at 8% ACN (5
min).
Raw MS data were analyzed using MaxQuant (developer version 1.5.5.4) with
the integrated Andromeda search engine39 to search the UniProt human FASTA
(downloaded 6 July 2015). The following Andromeda settings were used; initial
search mass tolerance of 20 ppm, main search mass tolerance of 6 ppm for parent
ions and 20 ppm for HCD fragment ions, trypsin speciﬁcity with a maximum of
two missed cleavages, cysteine carbamidomethylation as a ﬁxed modiﬁcation, and
N-acetylation of proteins, oxidized methionine, and acetylated lysine as variable
modiﬁcations. Acetylated peptides were ﬁltered for a minimum Andromeda score
of 40, as per the default settings for modiﬁed peptides. Known contaminants were
removed based on classiﬁcation by MaxQuant. The false discovery rate (FDR) was
estimated for peptides and proteins individually using a target-decoy approach
allowing a maximum of 1% false identiﬁcations from a reversed sequence database.
Calculation of acetylation stoichiometry. We used MaxQuant to analyze the
SILAC ratios of native and chemically acetylated peptides. In order to accurately
calculate stoichiometry it is important to compare the SILAC ratios of individual,
singly acetylated peptides from the “evidence.txt” table. We do not use the “Acetyl
(K)Sites.txt” table since the SILAC ratios of individual sites are sometimes derived
from multiple peptides. Likewise, entries in the “modiﬁcationSpeciﬁcPeptides.txt”
table can include different positions of acetylation within the same peptide
sequence. Starting with the “evidence.txt” table the following actions were
performed;
1. Remove all entries where Reverse=+ , Potential contaminant=+ , Acetyl
(K)= 0, and Acetyl (K)= 2. This removes reverse and contaminant entries
and results in only entries containing singly acetylated peptides.
2. The Modiﬁed Sequence was used as a unique identiﬁer to calculate the median
SILAC ratio and summed peptide intensity for multiple instances of any given
acetylated peptide in each experiment.
3. SILAC ratios were tested for agreement with the dilution series, allowing for
up to two-fold variability8. Stoichiometry was calculated using only peptides
that met these strict criteria.
4. Stoichiometry was calculated as follows; Stoichiometry (S), degree partial
chemical acetylation (C), dilution factor for acetylated peptides (D), and
SILAC ratio partial chemical acetylation/native acetylation (R). S= (C)/
((R*D)-(1-C)). The dilution factors (D) were as follows: Experiment 1, (~1%
D= 4.23), (~0.1% D= 42.3), (~0.01% D= 423), Experiment 2, (~1% D=
6.37), (~0.1% D= 63.7), (~0.01% D= 637). The median degree of partial
chemical acetylation (C) was 3.53% and 10.38%, for experiments 1 and 2,
respectively, (Supplementary Figure 1a).
The above mentioned .txt ﬁles can be found via the PRIDE40 partner repository
with the dataset identiﬁer PXD009994. Relative acetylation stoichiometry was
estimated using acetylation site intensity corrected for differences in protein
abundance, otherwise referred to as abundance-corrected intensity (ACI). ACI was
calculated by dividing acetylation site intensity by iBAQ protein abundance.
Validation by AQUA and spike-in. Two different unmodiﬁed AQUA peptides
(Thermo Scientiﬁc, AQUA quant pro) per protein were added to SILAC heavy-
labeled HeLa peptides to determine the concentration of each protein (CTTN,
NCL, and NAT10). Acetylated AQUA peptides were then added to ﬁnal stoi-
chiometry of 1%, 0.1%, or 0.01%, in accordance with each individual protein’s
concentration. Acetylated peptides were enriched as described above and analyzed
by mass spectrometry. For validation by recombinant acetylated protein spike-in,
recombinant acetylated protein was added to HeLa lysate and digested to deter-
mine the concentration of protein present in the lysate. Based on the initial ana-
lysis, recombinant HMGCL K48ac was added at a 1:1 (100%), 1:10 (10%), and
1:100 (1%) stoichiometry and MDH2 K239ac was added at a 1:1 (100%), 1:1,000
(0.1%), and 1:10,000 (0.01%) stoichiometry. Acetylated peptides were enriched
from the 1:10 and 1:100 dilutions (HMGCL) and the 1:1,000 and 1:10,000 dilutions
(MDH2) before analysis by mass spectrometry. The 1:1 dilutions were analyzed to
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determine the protein mixing ratio and to correct the stoichiometry measurements
accordingly. The mixing ratio of spike-in/HeLa was 1.48 for HMGCL and 0.70 for
MDH2.
Expression and puriﬁcation of recombinant acetylated proteins. MDH2
(K239AcK) and HMGCL (K48AcK) were expressed from a pRSF-Duet-vector
containing the HMGCL coding region with an amber-stop codon at the position
encoding for acetyl-L-lysine incorporation, and additionally the coding regions for
a synthetically evolved pair of Methanosarcina barkeri MS tRNACUA (MbtRNA-
CUA) and the acetyl-lysyl-tRNA-sythetase (AcKRS3). AcKRS3 and MbtRNACUA
enable the site-speciﬁc incorporation of acetyl-L-lysine into proteins as response to
an amber codon. This was done by supplementing the E. coli BL21 (DE3) culture
with 10 mM N-(e)-acetyl-lysine (Chem-Impex International, Inc.) and 20 mM
nicotinamide to inhibit the E. coli CobB deacetylase at an OD600 of 0.6 (37 °C, 160
rpm). Subsequently, the temperature was lowered to 18 °C and cells were grown for
another 30 min at 160 rpm. Protein expression was induced by addition of 200 µM
IPTG and protein expression conducted overnight (18 °C, 160 rpm). The cells were
harvested by centrifugation (4000 × g, 20 min) and resuspended in buffer A. Cell
lysis and protein puriﬁcation was performed as described above.
Histone western blot. HeLa cells were lysed by boiling in 2% lithium dodecyl
sulfate (LDS) (1x NuPAGE LDS Sample Buffer, ThermoFischer Scientiﬁc), fol-
lowed by sonication to disrupt genomic DNA. Proteins were separated on a 4-12
NuPAGE gel (ThermoFischer Scientiﬁc) and transferred to a nitrocellulose
membrane (BioRad). Acetylated proteins were visualized by immunoblot using
pan-anti-acetylated lysine antibody (Immunechem #ICP0380) at a 1/1000 dilution
and goat anti-rabbit horseradisch peroxidase (HRP) (BioRad, STAR124P) sec-
ondary antibody at a 1/5000 dilution.
Data analysis. Pearson’s correlation (r) and Wilcoxon tests were performed in R.
UniProt keyword analysis was performed using AGOTOOL10 with an uncorrected
P-value cutoff of 0.05. Word clouds were generated in R. To estimate histone
acetylation copy numbers we used the copy number estimate for histone H4 (5e7
per cell) for all four core histones. This is because copy number estimates for
histones are complicated by the presence of multiple isoforms of H2B, H2A, and
H3. The copy number estimate for H4 is consistent with a previous analysis that
estimated that core histones represent ~4% of the total protein in HeLa cells, and
with the DNA content of HeLa cells41. We furthermore used the median stoi-
chiometry for sites that occurred on multiple histone isoforms (such as H2B K5) to
avoid over-counting these sites.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The raw mass spectrometry data have been deposited to the ProteomeXchange
Consortium via the PRIDE40 partner repository with the dataset identiﬁer PXD009994.
The source data underlying Figs. 1a, 2a-b, 2d-e, 3a-d, 4a, 4c-d, 5a-c and Supplementary
Figs. 1a-c, 2a-c, and 3 are provided as a Source Data ﬁle. A reporting summary for this
Article is available as a Supplementary Information ﬁle. All other data supporting the
ﬁndings of this study are available from the corresponding authors upon reasonable
request.
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